PI3K

Qiagen and Foundation Medicine will develop tissue- and plasma-based companion tests to identify best responders to the PI3K inhibitor alpelisib

Based on the results of the SANDPIPER study in advanced, PIK3CA-mutated breast cancer, Genentech has decided not to advance development of the PI3 kinase inhibitor taselisib.

Amid concerns about buparlisib's toxicity profile, a study suggests there might be a benefit for a subpopulation of patients with a more targeted PI3K inhibitor.

Using an algorithm known as HotNet2, an international team has identified more than a dozen genetically altered sub-networks in thousands of tumor samples assessed for the Cancer Genome Atlas project.

Early data presented at SABCS suggests that ER/PR-positive breast cancer patients could respond particularly well to Genentech's PI3 kinase inhibitor.

Researchers from the Dana Farber Cancer Institute have published results of a preliminary study tracking the patterns of mutations in the two histological subtypes of cervical cancer, which they are now planning to put to the test in a clinical trial of PI3 kinase inhibitors.

Sharing a co-exclusive license to PI3K with Qiagen, Roche will develop assays for diagnostic markers to help subsidiary Genentech and external pharma partners to advance investigational drug candidates that inhibit PI3K.

Roche announced this week that the co-exclusive license for the biomarker would allow it to develop real-time and endpoint PCR assays to detect mutations in the PI3K oncogene, which would aid its subsidiary Genentech in the development of several investigational drug candidates.

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.